查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2073043

醫療保健供應鏈業務流程外包：市場佔有率分析、行業趨勢和統計數據、成長預測（2026-2031 年）

Healthcare Supply Chain BPO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)
出版日期: | 出版商: Mordor Intelligence | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

據 Mordor Intelligence 稱，2025 年醫療保健供應鏈 BPO 市場價值為 29.8 億美元，預計到 2031 年將從 2026 年的 31.7 億美元成長至 43 億美元，預測期（2026-2031 年）的複合年成長率為 6.30%。

醫療保健供應鏈業務流程外包市場-IMG1

本報告按類型、產品（庫存管理、採購、物流、供應商管理、訂單管理）、服務、技術（雲端技術、人工智慧、區塊鏈、RPA、物聯網）、組件、應用（醫院、製藥、醫療設備）、流程、部署模式、最終用戶和地區（北美、歐洲、亞太、中東和非洲、南美）進行細分。市場預測（價值，美元）。

全球醫療保健供應鏈業務流程外包市場的趨勢與洞察

RNA標靶藥物臨床研發管線的擴展

2026年中期，將有超過200家機構參與全球寡核苷酸臨床研發管線，為寡核苷酸CDMO市場帶來多元化且活躍的基本客群，並降低對少數申辦者的依賴。所有IND階段和後期臨床實驗室項目在獲得批准和商業化之前，均需使用符合GMP標準的材料。該研發管線正從以往專注於罕見疾病領域，逐漸轉向大規模的心血管代謝疾病領域，改變了預期的批量規模，並加大了商業供應計畫的壓力。傳統的合成方法無法滿足日益成長的慢性病適應症族群從千噸到噸級的不斷擴大的需求。

逐步將複雜的寡核苷酸合成和填充/精加工製程外包。

寡核苷酸CDMO市場正呈現明顯的外包趨勢。這是因為許多創新公司發現，內部難以管理複雜的寡核苷酸合成，以達到商業標準。 GalNAc偶聯siRNA的生產需要對組裝、脫保護、偶聯、純化和雜質分析等環節進行精細協調，每個環節在ICH標準下都面臨著獨特的技術挑戰。到2025年上半年，藥明康德的TIDES平台將支援69種分子的原料藥和製劑服務，這一數字在短短兩年內加倍。隨著產品轉向皮下注射和預填充劑型，灌裝和包裝流程的重要性日益凸顯，這要求企業具備超越原料藥合成的無菌生產能力。

長鏈寡核苷酸的製程複雜性高且對產量敏感

由於寡核苷酸CDMO市場採用逐步合成工藝，每次添加一個核苷酸，因此面臨巨大的技術挑戰。隨著序列長度的增加，這種方法的效率會累積。例如，一個20聚體的ASO至少需要20個偶聯循環，即使每一步的效率都很高，最終的產率也會顯著降低。如果引入硫代磷酸酯骨架、2'-氟取代或GalNAc配體等修飾，這項挑戰會更加突出，因為這些修飾會引入更多的副反應和分析複雜性。來自胜肽和小分子領域的供應商往往低估了生產計劃、雜質控制和批次失敗的風險，儘管市場需求強勁，但產能擴張卻受到阻礙。因此，商業性供應仍集中在擁有豐富營運經驗和良好業績記錄的公司手中。

細分市場分析

到2025年，交易型業務流程外包（BPO）將佔整個細分市場的41.68%，成為目前價值最高的合約模式。預計到2031年，綜合型BPO將以8.90%的複合年成長率成長，成為醫療保健供應鏈BPO市場中成長最快的類型。許多醫院、本地醫療服務提供者和經銷商開始將部分業務外包，最初僅限於訂單處理和發票處理等有限領域，並將工作量集中到標準化的工作流程中。

隨著買家尋求能夠集中管理採購、物流、庫存管理和分析的單一合作夥伴，包容性業務流程外包（BPO）模式正在擴展。隨著醫療機構在設定服務成果和追究供應商課責越來越有信心，這種模式也獲得了更多支持。流程導向BPO仍然是針對特定需求的、無需徹底改變營運模式的可行中間方案。未來，我們預計市場上將出現更多採用端到端結構的契約，以便對整個供應鏈功能進行更嚴格的控制。

到2025年，訂單管理將佔產品細分市場的36.23%，成為以金額為準最高的細分市場。採購服務預計到2031年將以9.25%的複合年成長率成長，成為成長最快的產品細分市場。醫院和醫療保健網路依靠訂單管理來處理涉及數千個SKU的大量訂單。這是因為這些工作流程具有重複性且易於標準化。

隨著客戶對採購、供應商風險評估、合約合規性和支出分析等方面的支援需求不斷成長，採購服務也隨之蓬勃發展。這種轉變推動了對更高附加價值營運支援的需求。物流和供應商管理也從中受益，因為企業正在實現供應商多元化並增強其網路韌性，從而逐步從以交易為中心轉型為策略職能。

到2025年，諮詢服務將佔該細分市場的36.74%，成為收入最高的服務類別。實施服務預計到2031年將以8.55%的複合年成長率成長，成為成長最快的服務類型。由於大多數外包專案都始於評估、設計、流程圖繪製和營運模式規劃，因此對諮詢服務的需求將保持強勁。

隨著越來越多的組織從規劃階段過渡到執行階段，需要進行設定、整合、測試和變更管理，實施服務的需求也不斷成長。此外，由於買家越來越重視部署後的持續性，支援和維護服務的重要性也日益凸顯。這種整體生命週期方法在 TraceLink 和 Genpact 等夥伴關係中得到了充分體現，這些合作專案將數位化供應鏈技術與託管服務相結合。

區域分析

2025年，北美佔據寡核苷酸CDMO市場39.55%的佔有率。這主要得益於美國和加拿大眾多RNA標靶藥物研發公司的強大實力，以及成熟的GMP生產設施。 Alnylam、Ionis、Arrowhead和Wave Life Sciences等公司，以及Agilent和Thermo Fisher Scientific等生產領域的領導企業，都為該地區的市場發展提供了支持。 Agilent於2026年推出的「Agilent Advanced Therapeutics」透過整合位於加拿大的BIOVECTRA和位於科羅拉多的Nucleic Acid Solutions，進一步增強了其在北美的CDMO能力。儘管對FDA法規的熟悉以及良好的GMP記錄進一步鞏固了該地區的地位，但隨著全球產能的擴張和交付優勢的減弱，其領先優勢可能會縮小。

歐洲仍然是寡核苷酸CDMO市場的關鍵技術中心，以德國和瑞士為主導，專注於高純度原料藥的生產和持續的資本投資。 BioSpring已在奧芬巴赫投資超過1億歐元（1.08億美元）新建一座核酸原料藥生產設施，預計2027年底完工。 Bachem在2025年撥款3.326億瑞士法郎用於網路擴張，計畫於2026年開始商業化生產，並計畫在2026年追加投資4億瑞士法郎。 Lonza預計2026年銷售額將成長11-12%，並將持續加強其在荷蘭的合成和抗體-寡核苷酸偶聯物生產能力​​。歐洲的優勢在於其技術專長、嚴格的監管以及滿足嚴苛品質要求的能力。

亞太地區是寡核苷酸CDMO市場成長最快的地區，主要得益於中國、韓國和日本產能的擴張，預計到2031年複合年成長率將達到24.56%。天津Asymchem的TJ4工廠擁有先進的加工設備，是一座綜合製藥生產設施，年寡核苷酸產能達180莫耳。藥明康德位於常州和泰興的原料藥製造地已於2025年通過FDA檢查，確保了對美國的持續供應。日本Catalyst公司已將其符合GMP規範的核酸原料藥產能擴大了十倍。南美和中東及非洲地區仍是新興市場，主要依賴從北美、歐洲和亞太地區進口。

其他好處

  • Excel格式的市場預測（ME）表
  • 3個月的分析師支持

目錄

第1章：引言

  • 研究假設和市場定義
  • 調查範圍

第2章：調查方法

第3章執行摘要

第4章 市場狀況

  • 市場概覽
  • 市場促進因素
    • 醫療採購業務日益複雜，給外包帶來了壓力。
    • 多層供應商網路中對庫存可視性的需求
    • 向基於雲端的流程協作和分析過渡
    • 藥品和醫療設備的監管可追溯性要求
    • 需要減少供應鏈中所佔用的營運資金。
    • 跨境供應鏈韌性與近岸外包計劃
  • 市場限制因素
    • 外包營運中存在的資料隱私和合約風險問題
    • 與傳統ERP、EDI和倉庫系統整合面臨的挑戰
    • 供應商網路和提供者網路之間的流程標準化程度有限
    • 醫療保健供應鏈工作流程中特定環節對人力資源的依賴
  • 價值和供應鏈分析
  • 監理情勢
  • 技術展望
  • 波特五力分析

第5章 市場規模與成長預測

  • 按類型
    • 交易型業務流程外包
    • 以流程為中心的業務流程外包
    • 綜合業務流程外包
  • 依產品
    • 庫存管理
    • 採購
    • 後勤
    • 供應商管理
    • 訂單管理
  • 按服務
    • 諮詢服務
    • 實施服務
    • 支援和維護服務
  • 透過技術
    • 基於雲端的
    • AI
    • 區塊鏈
    • RPA
    • 物聯網
  • 按組件
    • 軟體
    • 硬體
    • 服務
  • 透過使用
    • 醫院和診所
    • 製藥
    • 醫療設備
  • 透過流程
    • 訂單處理
    • 需求計劃
    • 供應商關係管理
  • 按實現類型
    • 現場
    • 基於雲端的
    • 混合
  • 最終用戶
    • 醫療保健提供者
    • 製藥公司
    • 醫療設備製造商
  • 按地區
    • 北美洲
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 其他歐洲國家
    • 亞太地區
      • 中國
      • 印度
      • 日本
      • 澳洲
      • 韓國
      • 其他亞太國家
    • 中東和非洲
      • GCC
      • 南非
      • 其他中東和非洲國家
    • 南美洲
      • 巴西
      • 阿根廷
      • 南美洲其他地區

第6章 競爭情勢

  • 市場集中度
  • 市佔率分析
  • 公司簡介
    • Accenture plc
    • Capgemini SE
    • Cardinal Health, Inc.
    • Cognizant Technology Solutions Corporation
    • Conduent Incorporated
    • Coupa Software Incorporated
    • EXLService Holdings, Inc.
    • Firstsource Solutions Limited
    • GeBBS Healthcare Solutions, Inc.
    • Genpact Limited
    • Global Healthcare Exchange, LLC
    • HCL Technologies Limited
    • IBM Corporation
    • Infosys Limited
    • JAGGAER, LLC
    • McKesson Corporation
    • NTT DATA Group Corporation
    • Premier, Inc.
    • Sutherland Global Services, Inc.
    • Tata Consultancy Services Limited
    • Tech Mahindra Limited
    • Vizient, Inc.
    • Wipro Limited
    • WNS（Holdings）Limited

第7章 市場機會與未來展望

簡介目錄
Product Code: 99307

According to Mordor Intelligence, the healthcare supply chain BPO market size was valued at USD 2.98 billion in 2025 and is estimated to grow from USD 3.17 billion in 2026 to reach USD 4.30 billion by 2031, at a CAGR of 6.30% during the forecast period (2026-2031).

Healthcare Supply Chain BPO - Market - IMG1

This report is Segmented by Type, Product (Inventory Management, Procurement, Logistics, Supplier Management, Order Management), Services, Technology (Cloud-Based, AI, Blockchain, RPA, IoT), Component, Application (Hospitals, Pharma, Medical Devices), Process, Deployment, End User, and Geography (North America, Europe, Asia-Pacific, MEA, South America). Market Forecasts in Value (USD).

Global Healthcare Supply Chain BPO Market Trends and Insights

Expanding Clinical Pipelines For RNA-Targeted Medicines

As of mid-2026, over 200 organizations contributed to the global oligonucleotide clinical pipeline, providing the oligonucleotide CDMO market with a diverse and active customer base, reducing reliance on a select few sponsors. Every IND-stage and late-stage program requires GMP material prior to approval and commercialization. The pipeline is increasingly leaning towards larger cardiometabolic opportunities, altering expected batch sizes and intensifying the pressure on commercial supply planning, a shift from the previous focus on rare diseases. Legacy synthesis footprints weren't designed to handle demands scaling from kilograms to tonnes across an expanding array of chronic indications.

Outsourcing Shift For Complex Oligonucleotide Synthesis And Fill-Finish

The oligonucleotide CDMO market is witnessing a pronounced outsourcing trend, as many innovators find it challenging to manage complex oligonucleotide synthesis to commercial standards internally. Manufacturing GalNAc-conjugated siRNA demands meticulous coordination across assembly, deprotection, conjugation, purification, and impurity profiling, with each step introducing distinct technical challenges under ICH standards. By the first half of 2025, WuXi AppTec's TIDES platform was servicing 69 molecules for both API and drug product services, a figure that has more than doubled in just two years. The fill-finish phase is gaining prominence as products transition to subcutaneous and prefilled formats, necessitating sterile capacities beyond mere API synthesis.

High Process Complexity And Yield Sensitivity In Long-Chain Oligonucleotides

The oligonucleotide CDMO market faces a significant technical challenge due to the stepwise synthesis process, where one nucleotide is added at a time. This method results in compounded efficiency losses for longer sequences. For example, a 20-mer ASO undergoes at least 20 coupling cycles, and even with high per-step efficiency, the final yield can drop noticeably. The challenge becomes more pronounced with modifications like phosphorothioate backbones, 2'-fluoro substitutions, or GalNAc ligands, which introduce additional side reactions and analytical complexities. Providers transitioning from peptides or small molecules often underestimate timelines, impurity management, and batch failure risks, leading to slower capacity ramp-up despite strong demand. Consequently, commercial supply remains concentrated among experienced companies with extensive operational histories.

Other drivers and restraints analyzed in the detailed report include:

  1. Rising Demand For Precision Medicine And Rare-Disease Programs
  2. Scale-Up Pressure From Dual-Route Manufacturing, Clinical And GMP
  3. Stringent Purity, Impurity, And Potency Control Requirements

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, Transactional BPO accounted for 41.68% of the segment, making it the largest contract model by current value. Comprehensive BPO is projected to grow at an 8.90% CAGR through 2031, emerging as the fastest-growing type in the healthcare supply chain BPO market. Many hospitals, regional providers, and distributors start outsourcing with limited scopes like order processing and invoice support, concentrating volume in standardized workflows.

Comprehensive BPO is expanding as buyers seek single partners to manage procurement, logistics, inventory, and analytics. This model gains traction as healthcare organizations grow confident in setting service outcomes and holding vendors accountable. Process-Specific BPO remains a middle-ground option for targeted outsourcing without a full operational shift. Over time, the market is expected to see more contracts adopting end-to-end structures for tighter control across supply chain functions.

Order Management held 36.23% of the product segment in 2025, making it the largest by value. Procurement Services is projected to grow at a 9.25% CAGR through 2031, becoming the fastest-growing product area. Hospitals and healthcare networks rely on Order Management for processing large order volumes across thousands of SKUs, as these workflows are repetitive and easier to standardize.

Procurement Services are growing as clients demand support in sourcing, supplier risk assessment, contract compliance, and spend analysis. This shift moves demand toward higher-value operational support. Logistics and Supplier Management are also benefiting as organizations diversify suppliers and enhance network resilience, driving a gradual shift from transaction-heavy to strategic functions.

Consulting Services held 36.74% of the segment in 2025, making it the largest services category by revenue. Implementation Services is projected to grow at an 8.55% CAGR through 2031, becoming the fastest-growing service type. Consulting remains strong as most outsourcing programs begin with assessment, design, process mapping, and operating model planning.

Implementation is growing as more organizations move from planning to execution, requiring setup, integration, testing, and change management. Support and Maintenance Services are also gaining importance as buyers prefer continuity post-deployment. This full life cycle approach is evident in partnerships like TraceLink and Genpact, combining digital supply chain technology with managed services.

Complete Report Scope:

  • By Type
    • Transactional BPO
    • Process-Specific BPO
    • Comprehensive BPO
  • By Product
    • Inventory Management
    • Procurement Services
    • Logistics Management
    • Supplier Management
    • Order Management
  • By Services
    • Consulting Services
    • Implementation Services
    • Support and Maintenance Services
  • By Technology
    • Cloud-Based Solutions
    • Artificial Intelligence
    • Blockchain
    • Robotic Process Automation
    • Internet of Things
  • By Component
    • Software
    • Hardware
    • Services
  • By Application
    • Hospitals and Clinics
    • Pharmaceutical Companies
    • Medical Device Manufacturers
  • By Process
    • Order Fulfillment
    • Demand Planning
    • Supplier Relationship Management
  • By Deployment
    • On-Premise
    • Cloud-Based
    • Hybrid
  • By End User
    • Healthcare Providers
    • Pharmaceutical Companies
    • Medical Device Manufacturers
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

In 2025, North America held a 39.55% share of the oligonucleotide CDMO market, driven by a strong presence of RNA-targeted drug developers and mature GMP sites in the U.S. and Canada. Companies like Alnylam, Ionis, Arrowhead, and Wave Life Sciences, along with manufacturing leaders such as Agilent and Thermo Fisher Scientific, anchor the region's market. Agilent's 2026 launch of Agilent Advanced Therapeutics integrated BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado, enhancing North America's CDMO capabilities. Familiarity with FDA regulations and established GMP track records further strengthen the region's position, though its lead may narrow as global capacity expands and delivery time advantages diminish.

Europe remains a key technical hub in the oligonucleotide CDMO market, led by Germany and Switzerland, with a focus on high-purity API manufacturing and sustained capital investments. BioSpring is investing over EUR 100 million (USD 108 million) in a new nucleic acid API facility in Offenbach, set for completion by late 2027. Bachem allocated CHF 332.6 million in 2025 to expand its network, initiated commercial production in 2026, and plans an additional CHF 400 million in CapEx for 2026. Lonza projects 11-12% sales growth for 2026 and continues to enhance its synthesis and antibody-oligonucleotide conjugate capabilities in the Netherlands. Europe's strength lies in its technical expertise, regulatory rigor, and ability to meet stringent quality demands.

Asia-Pacific is the fastest-growing region in the oligonucleotide CDMO market, with a 24.56% CAGR through 2031, driven by capacity expansions in China, South Korea, and Japan. Asymchem's TJ4 facility in Tianjin offers 180 mol per year of oligonucleotide capacity, supported by advanced processing tools and an integrated drug product facility. WuXi AppTec's API sites in Changzhou and Taixing passed FDA inspections in 2025, ensuring continued U.S. supply. Japan's Nippon Shokubai is expanding its GMP-compliant nucleic acid API capacity tenfold. South America and the Middle East & Africa remain emerging markets, primarily relying on imports from North America, Europe, and Asia-Pacific hubs.

  1. Accenture
  2. Capgemini
  3. Cardinal Health
  4. Cognizant
  5. Conduent Incorporated
  6. Coupa Software Incorporated
  7. EXLService Holdings, Inc.
  8. Firstsource Solutions Limited
  9. GeBBS Healthcare Solutions, Inc.
  10. Genpact
  11. Global Healthcare Exchange, LLC
  12. HCL Technologies Limited
  13. IBM
  14. Infosys
  15. JAGGAER, LLC
  16. Mckesson
  17. NTT DATA Group Corporation
  18. Premier, Inc.
  19. Sutherland Global Services, Inc.
  20. Tata Consultancy Services
  21. Tech Mahindra Limited
  22. Vizient
  23. Wipro
  24. WNS (Holdings) Limited

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Outsourcing Pressure From Healthcare Procurement Complexity
    • 4.2.2 Demand for Inventory Visibility Across Multi-Tier Supplier Networks
    • 4.2.3 Shift Toward Cloud-Enabled Process Orchestration and Analytics
    • 4.2.4 Regulatory Traceability Requirements for Pharmaceuticals and Medical Devices
    • 4.2.5 Provider Need to Reduce Working Capital Locked in Supply Chains
    • 4.2.6 Cross-Border Supply Chain Resilience and Nearshoring Programs
  • 4.3 Market Restraints
    • 4.3.1 Data Privacy and Contractual Risk Concerns in Outsourced Operations
    • 4.3.2 Integration Friction With Legacy ERP, EDI, and Warehouse Systems
    • 4.3.3 Limited Process Standardization Across Provider and Supplier Networks
    • 4.3.4 Talent Dependence for Domain-Specific Healthcare Supply Chain Workflows
  • 4.4 Value and Supply Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

  • 5.1 By Type
    • 5.1.1 Transactional BPO
    • 5.1.2 Process-Specific BPO
    • 5.1.3 Comprehensive BPO
  • 5.2 By Product
    • 5.2.1 Inventory Management
    • 5.2.2 Procurement Services
    • 5.2.3 Logistics Management
    • 5.2.4 Supplier Management
    • 5.2.5 Order Management
  • 5.3 By Services
    • 5.3.1 Consulting Services
    • 5.3.2 Implementation Services
    • 5.3.3 Support and Maintenance Services
  • 5.4 By Technology
    • 5.4.1 Cloud-Based Solutions
    • 5.4.2 Artificial Intelligence
    • 5.4.3 Blockchain
    • 5.4.4 Robotic Process Automation
    • 5.4.5 Internet of Things
  • 5.5 By Component
    • 5.5.1 Software
    • 5.5.2 Hardware
    • 5.5.3 Services
  • 5.6 By Application
    • 5.6.1 Hospitals and Clinics
    • 5.6.2 Pharmaceutical Companies
    • 5.6.3 Medical Device Manufacturers
  • 5.7 By Process
    • 5.7.1 Order Fulfillment
    • 5.7.2 Demand Planning
    • 5.7.3 Supplier Relationship Management
  • 5.8 By Deployment
    • 5.8.1 On-Premise
    • 5.8.2 Cloud-Based
    • 5.8.3 Hybrid
  • 5.9 By End User
    • 5.9.1 Healthcare Providers
    • 5.9.2 Pharmaceutical Companies
    • 5.9.3 Medical Device Manufacturers
  • 5.10 By Geography
    • 5.10.1 North America
      • 5.10.1.1 United States
      • 5.10.1.2 Canada
      • 5.10.1.3 Mexico
    • 5.10.2 Europe
      • 5.10.2.1 Germany
      • 5.10.2.2 United Kingdom
      • 5.10.2.3 France
      • 5.10.2.4 Italy
      • 5.10.2.5 Spain
      • 5.10.2.6 Rest of Europe
    • 5.10.3 Asia-Pacific
      • 5.10.3.1 China
      • 5.10.3.2 India
      • 5.10.3.3 Japan
      • 5.10.3.4 Australia
      • 5.10.3.5 South Korea
      • 5.10.3.6 Rest of Asia-Pacific
    • 5.10.4 Middle East and Africa
      • 5.10.4.1 GCC
      • 5.10.4.2 South Africa
      • 5.10.4.3 Rest of Middle East and Africa
    • 5.10.5 South America
      • 5.10.5.1 Brazil
      • 5.10.5.2 Argentina
      • 5.10.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
    • 6.3.1 Accenture plc
    • 6.3.2 Capgemini SE
    • 6.3.3 Cardinal Health, Inc.
    • 6.3.4 Cognizant Technology Solutions Corporation
    • 6.3.5 Conduent Incorporated
    • 6.3.6 Coupa Software Incorporated
    • 6.3.7 EXLService Holdings, Inc.
    • 6.3.8 Firstsource Solutions Limited
    • 6.3.9 GeBBS Healthcare Solutions, Inc.
    • 6.3.10 Genpact Limited
    • 6.3.11 Global Healthcare Exchange, LLC
    • 6.3.12 HCL Technologies Limited
    • 6.3.13 IBM Corporation
    • 6.3.14 Infosys Limited
    • 6.3.15 JAGGAER, LLC
    • 6.3.16 McKesson Corporation
    • 6.3.17 NTT DATA Group Corporation
    • 6.3.18 Premier, Inc.
    • 6.3.19 Sutherland Global Services, Inc.
    • 6.3.20 Tata Consultancy Services Limited
    • 6.3.21 Tech Mahindra Limited
    • 6.3.22 Vizient, Inc.
    • 6.3.23 Wipro Limited
    • 6.3.24 WNS (Holdings) Limited

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

  • 7.1 White-Space and Unmet-Need Assessment